DDInter58 DDInter1658
Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Aluminum hydroxide {u} (Compound) causes {v} (Side Effect) Venous thrombosis
Aluminum hydroxide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Moexipril
Aluminum hydroxide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ponatinib
Aluminum hydroxide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Moxifloxacin
Aluminum hydroxide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Riociguat
Aluminum hydroxide {u} may lead to a major life threatening interaction when taken with {v} Paricalcitol
Aluminum hydroxide {u} may lead to a major life threatening interaction when taken with {v} Calcium citrate
Aluminum hydroxide (Compound) causes Venous thrombosis (Side Effect)
Aluminum hydroxide may cause a minor interaction that can limit clinical effects when taken with Moexipril
Aluminum hydroxide may cause a minor interaction that can limit clinical effects when taken with Ponatinib
Aluminum hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin
Aluminum hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Riociguat
Aluminum hydroxide may lead to a major life threatening interaction when taken with Paricalcitol
Aluminum hydroxide may lead to a major life threatening interaction when taken with Calcium citrate